# Renin-Angiotensin-Aldosterone System Inhibitors, Hypertension, and COVID-19

> **NCT04374695** · — · UNKNOWN · sponsor: **Versailles Hospital** · enrollment: 700 (estimated)

## Conditions studied

- COVID-19

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04374695
- **Lead sponsor:** Versailles Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-01
- **Primary completion:** 2020-06-01
- **Final completion:** 2020-07-01
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2020-05-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04374695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04374695, "Renin-Angiotensin-Aldosterone System Inhibitors, Hypertension, and COVID-19". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04374695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*